<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03872843</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00056720</org_study_id>
    <nct_id>NCT03872843</nct_id>
  </id_info>
  <brief_title>Opioid Free Management After Ureteroscopy</brief_title>
  <official_title>A Prospective Double Blind Randomized Control Trial Comparing Opioid to Non-Opioid Protocol in Managing Postoperative Pain After Ureteroscopy With Stent Placement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to compare how well two medications work to control
      post-operative pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a randomized double blinded control trial with subjects randomized to either
      opioid group (Norco 5-325 milligram) or a non-opioid group (Ibuprofen 400 milligram).
      Subjects with a renal stones who are consented for a ureteroscopy will be eligible for the
      study. Subjects eligible for the study will have a discussion with the study team member
      about treatment options. Subjects can either elect not to be in the study and actively choose
      which treatment is preferable, or the subject can choose to enter the study and be randomized
      to one of these treatment arms. The ureteroscopy will be performed using standard of care
      instruments and techniques. No changes to operative technique will be performed for subjects
      in the study vs regular patients undergoing the same procedure. Post operatively;
      investigators plan to discharge all subjects home from the recovery unit. All subjects will
      be seen one week after surgery for follow up, questioner filling and stent removal.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 19, 2019</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double-blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Amount of pain medication in each arm</measure>
    <time_frame>up to 7 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of additional pain medication</measure>
    <time_frame>up to 7 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of pain medication refills</measure>
    <time_frame>up to 7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Emergency Department visits for postoperative Genitourinary Symptoms</measure>
    <time_frame>up to 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Phone Calls to Clinic</measure>
    <time_frame>up to 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Index</measure>
    <time_frame>up to 7 days</time_frame>
    <description>Ureteral stent symptom questionnaire: Urinary Index Score (11-55). Higher scores indicates worse outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Index</measure>
    <time_frame>up to 7 days</time_frame>
    <description>Ureteral stent symptom questionnaire: Pain Index Score (6-30) Higher scores indicates worse outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General Health Index</measure>
    <time_frame>up to 7 days</time_frame>
    <description>Ureteral stent symptom questionnaire: General Health Index Score (6-30). Higher scores indicates worse outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work Performance questionnaire</measure>
    <time_frame>up to 7 days</time_frame>
    <description>Ureteral stent symptom questionnaire: Work Performance Score (3-15). Higher scores indicates worse outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexual Matters questionnaire</measure>
    <time_frame>up to 7 days</time_frame>
    <description>Ureteral stent symptom questionnaire:Sexual Matters( 2-10) Higher scores indicates worse outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional Problems with the stent in situ questionnaire</measure>
    <time_frame>up to 7 days</time_frame>
    <description>Ureteral stent symptom questionnaire: Additional Problems with the stent in situ (4-17) Higher scores indicates worse outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Quality of life with the stent in situ questionnaire</measure>
    <time_frame>up to 7 days</time_frame>
    <description>Ureteral stent symptom questionnaire: Global Quality of life with the stent in situ (1-7). Higher scores indicates worse outcomes.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Kidney Stone</condition>
  <arm_group>
    <arm_group_label>Opioid Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group includes subjects with renal stones who are consented for a ureteroscopy. They will be randomized to Norco 5milligram-325milligram Tablet for postoperative pain after ureteroscopy with stent placement.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Opioid Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group includes subjects with renal stones who are consented for a ureteroscopy. They will be randomized to Ibuprofen 400 milligram for postoperative pain after ureteroscopy with stent placement.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norco 5milligram-325milligram Tablet</intervention_name>
    <description>Designated coated 7 days supply of pain medication (Norco 5 milligram-325milligram Tablet) will be sent home with discharged subjects. Pain medication is administered/scheduled 4 times per day until the stent will be removed in clinic a week later.</description>
    <arm_group_label>Opioid Group</arm_group_label>
    <other_name>Opioid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen 400 MILLIGRAM in 1 TABLET ORAL TABLET, FILM COATED</intervention_name>
    <description>Designated coated 7 days supply of pain medication (Ibuprofen 400 milligram) will be sent home with discharged subjects. Pain medication is administered/scheduled 4 times a day as needed until the stent will be removed in clinic a week later.</description>
    <arm_group_label>Non-Opioid Group</arm_group_label>
    <other_name>Non-Opioid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ureteroscopy performed for renal stones

          -  Age over 18 years

          -  Two kidneys

        Exclusion Criteria:

          -  Solitary Kidney

          -  Poor kidney function (GFR&lt;30)

          -  Allergy to either Ibuprofen or Norco

          -  Pelvic Kidney
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jorge Gutierrez-Aceves, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Finney RP. Experience with new double J ureteral catheter stent. J Urol. 1978 Dec;120(6):678-81.</citation>
    <PMID>731804</PMID>
  </reference>
  <reference>
    <citation>Assimos D, Krambeck A, Miller NL, Monga M, Murad MH, Nelson CP, Pace KT, Pais VM Jr, Pearle MS, Preminger GM, Razvi H, Shah O, Matlaga BR. Surgical Management of Stones: American Urological Association/Endourological Society Guideline, PART II. J Urol. 2016 Oct;196(4):1161-9. doi: 10.1016/j.juro.2016.05.091. Epub 2016 May 27.</citation>
    <PMID>27238615</PMID>
  </reference>
  <reference>
    <citation>Joshi HB, Okeke A, Newns N, Keeley FX Jr, Timoney AG. Characterization of urinary symptoms in patients with ureteral stents. Urology. 2002 Apr;59(4):511-6.</citation>
    <PMID>11927301</PMID>
  </reference>
  <reference>
    <citation>Mosli HA, Farsi HM, al-Zimaity MF, Saleh TR, al-Zamzami MM. Vesicoureteral reflux in patients with double pigtail stents. J Urol. 1991 Oct;146(4):966-9.</citation>
    <PMID>1895452</PMID>
  </reference>
  <reference>
    <citation>Chew BH, Knudsen BE, Nott L, Pautler SE, Razvi H, Amann J, Denstedt JD. Pilot study of ureteral movement in stented patients: first step in understanding dynamic ureteral anatomy to improve stent comfort. J Endourol. 2007 Sep;21(9):1069-75.</citation>
    <PMID>17941789</PMID>
  </reference>
  <reference>
    <citation>Al-Kandari AM, Al-Shaiji TF, Shaaban H, Ibrahim HM, Elshebiny YH, Shokeir AA. Effects of proximal and distal ends of double-J ureteral stent position on postprocedural symptoms and quality of life: a randomized clinical trial. J Endourol. 2007 Jul;21(7):698-702.</citation>
    <PMID>17705753</PMID>
  </reference>
  <reference>
    <citation>Joshi HB, Newns N, Stainthorpe A, MacDonagh RP, Keeley FX Jr, Timoney AG. Ureteral stent symptom questionnaire: development and validation of a multidimensional quality of life measure. J Urol. 2003 Mar;169(3):1060-4.</citation>
    <PMID>12576846</PMID>
  </reference>
  <reference>
    <citation>Theisen K, Jacobs B, Macleod L, Davies B. The United States opioid epidemic: a review of the surgeon's contribution to it and health policy initiatives. BJU Int. 2018 Nov;122(5):754-759. doi: 10.1111/bju.14446. Epub 2018 Jul 26. Review.</citation>
    <PMID>29896932</PMID>
  </reference>
  <reference>
    <citation>Large T, Heiman J, Ross A, Anderson B, Krambeck A. Initial Experience with Narcotic-Free Ureteroscopy: A Feasibility Analysis. J Endourol. 2018 Oct;32(10):907-911. doi: 10.1089/end.2018.0459. Epub 2018 Sep 12.</citation>
    <PMID>30039709</PMID>
  </reference>
  <reference>
    <citation>Sobel DW, Cisu T, Barclay T, Pham A, Callas P, Sternberg K. A Retrospective Review Demonstrating the Feasibility of Discharging Patients Without Opioids After Ureteroscopy and Ureteral Stent Placement. J Endourol. 2018 Nov;32(11):1044-1049. doi: 10.1089/end.2018.0539. Epub 2018 Oct 23. Review.</citation>
    <PMID>30244594</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 11, 2019</study_first_submitted>
  <study_first_submitted_qc>March 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2019</study_first_posted>
  <last_update_submitted>April 16, 2020</last_update_submitted>
  <last_update_submitted_qc>April 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ureteroscopy</keyword>
  <keyword>Opioid</keyword>
  <keyword>Non-Opioid</keyword>
  <keyword>Stent Placement</keyword>
  <keyword>Nephrolithiasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Calculi</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>We will not share.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

